



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**20 October 2020**

---

## **Bionomics Successfully Completes Retail Entitlement Offer**

Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (**Bionomics**) is pleased to announce the successful completion of the retail component of its 1 for 12.54 pro rata accelerated non-renounceable entitlement offer, announced on Thursday, 24 September 2020 (**Entitlement Offer**).

Completion of the retail component (**Retail Entitlement Offer**) represents the final stage of Bionomics' Entitlement Offer, which together with the institutional component, was an equity raising of approximately A\$2,173,320 before costs.

The Retail Entitlement Offer closed at 5.00pm (Adelaide time) on Thursday, 15 October 2020 and raised approximately \$1.2 million from the offer of new fully paid ordinary shares in Bionomics (**New Shares**) at the offer price of \$0.04 per New Share. The Entitlement Offer was well supported by eligible retail shareholders. Eligible retail shareholders applied for approximately 23.5 million shares aggregating to approximately A\$0.9 million of New Shares pursuant to their entitlements (representing a take up rate of approximately 74%).

Eligible retail shareholders subscribed for a further approximately 38.6 million additional New Shares in excess of their entitlement (up to a maximum of 100% of their entitlement) aggregating to approximately A\$1.54 million through the Retail Oversubscription Facility. Applications under the Retail Oversubscription Facility were in excess of the approximately 8.45 million shares or \$338,000 shortfall and were scaled back on a pro-rata basis.

Commenting on the outcome of the Entitlement Offer, Bionomics' Executive Chairman, Dr Errol De Souza said, *"Following on from the strong support received under the institutional component of the Entitlement Offer, the success of the Retail Entitlement Offer demonstrates the confidence of Bionomics' shareholders in the direction of the Company and the opportunities presented by progressing the development programme for BNC210 for the treatment of PTSD."*

Allotment of New Shares under the Retail Entitlement Offer is expected to take place on Thursday, 22 October 2020 and normal trading on ASX is expected to commence on Friday, 23 October 2020.

New Shares issued under the Retail Entitlement Offer will rank equally in all respects with existing shares. Shareholders should confirm their holding before trading in New Shares.

**AUTHORISED BY THE EXECUTIVE CHAIRMAN, DR ERROL DE SOUZA**

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
Bionomics Limited  
31 Dalglish St,  
Thebarton, South Australia  
+61 8 8354 6100

**About Bionomics Limited**

Bionomics Limited (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 ( $\alpha 7$ ) nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co in the US and Canada) and a pipeline of pre-clinical ion channel programs targeting pain, depression, cognition and epilepsy.

**Important information**

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which such an offer would be illegal. Neither the entitlements nor the New Shares to be offered and sold in the Entitlement Offer have been, or will be, registered under the U.S. Securities Act of 1933 (**U.S. Securities Act**) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the entitlements may not be exercised or taken up by, and the New Shares may not be offered or sold, directly or indirectly, to, persons in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities law of any state or other jurisdiction of the United States.